Evidence map›Paper›PMID 39299757›Full record

ArticleLupus science & medicine2024

Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus.

Yanjie Hao, Dylan Hansen, Worawit Louthrenoo, Yi-Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, Shue-Fen Luo, Yeong-Jian Jan Wu, Sandra Navarra and 24 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Lupus science & medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Yanjie HaoTeaching Hospital Kandy, Kandy, Sri Lanka.ORCID 0000-0001-8715-259X
Dylan HansenPeking University First Hospital, Beijing, China.
Worawit LouthrenooRheumatology, St Vincent's Hospital Melbourne Pty Ltd, Fitzroy, Victoria, Australia.
Yi-Hsing ChenChiang Mai University Faculty of Medicine, Chiang Mai, Thailand.
Jiacai ChoSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.ORCID 0000-0002-4477-3430
Aisha LateefNational University Hospital Singapore Pte Ltd, Singapore.
Laniyati HamijoyoDepartment of Medicine, Woodlands Health, Singapore.ORCID 0000-0002-1310-674X
Shue-Fen LuoRheumatology Division, Internal Medicine, Padjadjaran University, Bandung, Indonesia.
Yeong-Jian Jan WuDivision of Rheumatology, Allergy, and Immunology, Chang Gung Memorial Hospital Linkou, Taoyuan, Taiwan.
Sandra NavarraDepartment of Medicine, Division of Allergy, Immunology and Rheumatology, Chang Gung University College of Medicine, Taoyuan, Taiwan.ORCID 0000-0003-0094-8654
Leonid ZamoraUniversity of Santo Tomas Hospital, Manila, Philippines.
Zhanguo LiUniversity of Santo Tomas Faculty of Medicine and Surgery, Manila, Philippines.
Sargunan SockalingamPeking University Health Science Center, Beijing, China.
Yasuhiro KatsumataUniversity of Malaya Faculty of Medicine, Kuala Lumpur, Malaysia.ORCID 0000-0003-1654-0119
Masayoshi HarigaiDivision of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan.
Zhuoli ZhangInstitute of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan.ORCID 0000-0001-7219-9141
Madelynn ChanRheumatology and Clinical Immnunology, Peking University First Hospital, Beijing, China.
Jun KikuchiTan Tock Seng Hospital, Singapore.ORCID 0000-0003-3231-8841
Tsutomu TakeuchiDivision of Rheumatology, Keio University School of Medicine Department of Internal Medicine, Shinjuku-ku, Tokyo, Japan.
Sang-Cheol BaeDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine Graduate School of Medicine, Shinjuku-ku, Tokyo, Japan.ORCID 0000-0003-4658-1093
Fiona GoldblattRheumatology, Hanyang University Hospital for Rheumatic Diseases, Seongdong-gu, Seoul, The Republic of Korea.
Sean O'NeillRepatriation General Hospital, Daw Park, South Australia, Australia.
Kristine NgLiverpool Hospital, Liverpool, New South Wales, Australia.
B M D B BasnayakeNorth Shore Hospital, Auckland, New Zealand.
Nicola TugnetAuckland District Health Board, Auckland, New Zealand.
Yoshiya TanakaFirst Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Fukuoka, Japan.ORCID 0000-0002-0807-7139
Chak Sing LauThe University of Hong Kong, Hong Kong, Hong Kong.ORCID 0000-0001-6698-8355
Ning LiSchool of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.ORCID 0000-0001-8013-5041
Vera GolderRheumatology, Monash University Faculty of Medicine Nursing and Health Sciences, Clayton, Victoria, Australia.
Alberta HoiSchool of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-9416-7383
Rangi Kandane-RathnayakeSchool of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.ORCID 0000-0001-5397-1482
Eric MorandSchool of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-9507-3338
Shereen OonDepartment of Medicine at St. Vincent's Hospital, The University of Melbourne, Melbourne, Victoria, Australia.
Mandana NikpourThe University of Sydney School of Public Health, Sydney, New South Wales, Australia mandana.nikpour@sydney.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe lupus low disease activity state (LLDAS) allows for certain clinical and/or serological activity of SLE, provided overall disease activity does not exceed predefined cut-offs. This study aimed to evaluate the outcomes of patients who achieved LLDAS with clinical activity, serological activity only or neither clinical nor serological activity.

methodsPatients with SLE enrolled in a prospective multinational cohort from March 2013 to December 2020 who were in LLDAS at least once were included. Visits that fulfilled both LLDAS and Definition of Remission in SLE (DORIS) criteria were excluded.

results2099 patients were included, with median follow-up of 3.5 (IQR 1.3-5.8) years. At 6150 visits, patients were in LLDAS but not DORIS criteria; of these 1280 (20.8%) had some clinical activity, 3102 (50.4%) visits had serological activity only and 1768 (28.8%) visits had neither clinical nor serological activity. Multivariable regression analysis showed that compared with non-LLDAS, all three subsets of LLDAS had a protective association with flares in the ensuing 6 months and damage accrual in the ensuing 36 months. LLDAS with no clinical or serological activity had a significantly stronger protective association with severe flares in the ensuing 6 months compared with LLDAS with clinical activity (HR 0.47, 95% CI (0.27 to 0.82), p=0.007).

conclusionsLLDAS without any clinical activity accounted for almost 80% of LLDAS visits. This study confirms that all subsets of LLDAS are associated with reduced flare and damage accrual. However, LLDAS without any clinical or serological activity has the strongest protective association with severe flares.

Indexed as

Lupus Erythematosus, SystemicSeverity of Illness IndexAdultFemaleFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesRemission Inductionepidemiologyoutcome assessment, health caresystemic lupus erythematosus

Identifiers

PMID39299757
PMCPMC11418568

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.